Hostname: page-component-89b8bd64d-72crv Total loading time: 0 Render date: 2026-05-09T08:03:51.246Z Has data issue: false hasContentIssue false

An analysis of the population genetics of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy

Published online by Cambridge University Press:  26 February 2007

A. E. SCHWAB
Affiliation:
Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, Canada, H9X 3V9
T. S. CHURCHER
Affiliation:
Department of Infectious Disease Epidemiology, St Mary's Campus, Imperial College London, Norfolk Place, London W2 1PG, UK
A. J. SCHWAB
Affiliation:
Research Institute of the McGill University, Health Centre General Hospital, 1650 Cedar Avenue, Montreal, Quebec, Canada, H3G 1A4
M.-G. BASÁÑEZ
Affiliation:
Department of Infectious Disease Epidemiology, St Mary's Campus, Imperial College London, Norfolk Place, London W2 1PG, UK
R. K. PRICHARD*
Affiliation:
Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, Canada, H9X 3V9
*
*Corresponding author: Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, Canada, H9X 3V9. Tel: +1 514 398 7729. Fax: +1 514 398 7857. E-mail: roger.prichard@mcgill.ca

Summary

Currently, annual mass treatments with albendazole (ABZ) plus ivermectin (IVM) or diethylcarbamazine (DEC) are administered under the Global Programme to Eliminate Lymphatic Filariasis (GPELF). Drug resistance against both ABZ and IVM is prevalent in nematodes of veterinary importance, raising awareness that if anthelmintic resistance were to develop among Wuchereria bancrofti populations, this would jeopardize GPELF's goals. Genetic structure was incorporated into an existing transmission dynamics model for lymphatic filariasis (LF) to investigate the potential development of concurrent resistance to ABZ and IVM. The resultant models explore the impact of different inheritance modes of resistance to ABZ and IVM on the likely risk of treatment failure under our model assumptions. Results indicate that under ABZ+IVM combination, selection for resistance to one drug is enhanced if resistance to the other drug is already present. Excess parasite homozygosity may increase selection for dominant IVM resistance via enhancing the frequency of recessive ABZ resistance. The model predicts that if multiple resistance genes are associated with different efficacy properties of a drug combination, then examining changes at single loci may be misleading. Sampling schemes in genetic epidemiological surveys investigating the frequency of an allele under selection should consider host age, as individuals of different ages may acquire parasites at different rates.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable